Publications

• 07.12.2021  |  Clinical Infectious Diseases – Patient access in fourteen high-income countries to new antibacterials approved by the FDA, EMA, PMDA, or Health Canada, 2010-2020 Download
• 06.23.2021  |  5 Years of CARB-X Progress – Addressing the Global Antibacterial Resistance Threat: Innovation to prepare for the future Download
• 03.23.2021  |  Stewardship and Access Plan Development Guide Download
• 03.23.2021  |  Indian Priority Pathogen List jointly developed by DBT and WHO India Office Download
• 01.25.2021  |  Clinical Infectious Diseases – Leveraging Vaccines to Reduce Antibiotic Use and Prevent Antimicrobial Resistance: a WHO Action Framework Download
• 01.02.2021  |  CDDEP – The State of the World’s Antibiotics 2021 – A Global Analysis of Antimicrobial Resistance and Its Drivers Download
• 11.11.2020  |  The Lancet – COVID-19 pneumonia and the appropriate use of antibiotics Download
• 10.23.2020  |  Nature – Improving data sharing to increase the efficiency of antibiotic R&D Download
• 10.11.2020  |  United States National Action Plan for Combating Antibiotic-Resistant Bacteria, 2020-2025 Download
• 06.25.2020  |  Clinical Infectious Diseases – Antibacterial R&D at a crossroads: We’ve pushed as hard as we can … now we need to start pulling! Download
• 06.19.2020  |  Innovation in Antimicrobial Resistance: The CARB-X Perspective Download
• 06.01.2020  |  Translational Research – Evaluating for-profit public benefit corporations as an additional structure for antibiotic development and commercialization Download
• 04.30.2020  |  A One Health framework to estimate costs of antimicrobial resistance Download
• 04.20.2020  |  Lancet Infectious Diseases – The Lancet Infectious Diseases Commission on antimicrobial resistance: 6 years later Download
• 01.30.2020  |  Clinical Infectious Diseases – Antibiotic development incentives that reflect societal value of antibiotics Download